The Dark Side of Private Equity: When Profit Margins Trump Patient Sight
Private equity has a reputation for driving growth, scaling companies, and maximizing returns. But a growing body of evidence suggests that in healthcare—specifically ophthalmology—some firms are willing to let patients lose their sight rather than sacrifice their margins. Here’s the data, the playbook, and what revenue teams at SaaS and tech companies serving healthcare need to know.
The Study That Should Make You Uncomfortable
New research, covered by ProPublica and The New Yorker, reveals a disturbing trend: after private equity firms acquire ophthalmology practices, emergency surgeries for serious eye conditions decline significantly. The study, conducted by researchers at Harvard Medical School, analyzed Medicare claims data from 2015 to 2020. It compared practices acquired by private equity to those that remained independent.
The headline finding? Patients at PE-owned practices were 11% less likely to receive emergency surgery for acute eye conditions like retinal detachment, endophthalmitis, or open-globe injuries. These are conditions where every hour counts. Delaying treatment by even 12 hours can mean permanent vision loss.
Let that sink in. A 11% reduction in emergency procedures doesn’t sound huge on paper—until you realize that someone is going blind because a quarterly earnings report looked better.
How Private Equity Changes Clinical Decision-Making
Private equity firms didn’t buy these practices to improve patient outcomes. They bought them to drive revenue. The playbook is predictable, and if you’re in B2B tech, you’ve seen it before:
1. Profit Margin Pressure
PE firms typically load portfolio companies with debt and demand aggressive EBITDA targets. In ophthalmology, that means cutting costs where possible. Emergency surgeries are expensive—they require on-call staff, specialized equipment, and longer OR times. A scheduled cataract surgery? That’s predictable, profitable, and low-acuity.
2. Incentive Misalignment
Physicians in PE-owned practices often face compensation tied to productivity metrics. The study authors suggest that surgeons may be incentivized to avoid low-margin emergency cases. Instead, they focus on high-volume, high-margin elective procedures. The result? A patient with a detached retina gets told to “wait and see” while the surgeon books another cataract surgery.
3. Reduced Capacity for Emergencies
Private equity firms acquired 8,500 physician practices between 2013 and 2020, per the American Antitrust Institute. In ophthalmology, PE-owned practices often consolidate multiple clinics into centralized surgical centers. That reduces the local capacity for emergency care. If the only retina specialist in a region is now owned by a PE firm that’s optimized for elective surgeries, who answers the 2 AM call?
The Revenue Teams’ Wake-Up Call
If you’re selling to healthcare providers—particularly those owned by private equity—you need to understand this dynamic. Here’s why it matters for your GTM strategy:
You’re Not Selling to Doctors Anymore
When a practice is PE-owned, the decision-makers are investment managers, not physicians. Your sales pitch needs to speak to ROI, EBITDA impact, and scalability. But here’s the twist: the end users (doctors) are increasingly disillusioned. They see their clinical autonomy stripped away. If your product helps them reclaim that autonomy—by streamlining workflows, reducing administrative burden, or improving patient outcomes—you have a massive wedge.
Compliance and Ethical Selling
SaaS vendors selling into PE-owned healthcare must navigate a minefield. Your tool might improve efficiency, but if it’s used to squeeze more high-margin procedures at the expense of emergency care, you’re complicit. Smart buyers are asking: “Does this technology help us treat the sickest patients, or just the most profitable ones?”
The Data Story
The Harvard study used Medicare claims data. That’s a goldmine for analytics vendors. PE firms love data-driven decisions—until the data shows they’re harming patients. If you can offer transparency into referral patterns, surgical outcomes, and emergency utilization, you can help providers resist the pressure to deprioritize emergencies.
The Playbook for Tech Leaders
Here’s how to position your product in this environment:
1. Build for Clinical Integrity
Market your solution as a tool that preserves clinical decision-making. “Our platform ensures that no patient falls through the cracks—even when profit margins are tight.” That’s a powerful message for physicians who feel trapped by PE ownership.
2. Target the Uncaptured
Not all ophthalmology practices are PE-owned. Independent practices are fighting back by forming their own groups (think: IPAs or ACOs). They’re hungry for technology that helps them compete on quality, not just volume. Sell them the vision of “patient-first growth” versus “profit-only scaling.”
3. Audit Your Own Metrics
If you’re a PE-backed SaaS company, you’re not immune. Ask yourself: Are our OKRs driving the right behaviors? If your sales team is incentivized to close deals with large PE-owned groups, you might be inadvertently supporting a system that prioritizes profit over patient safety. Build ethical guardrails into your compensation model.
The Human Cost of the 11% Reduction
Let’s put a face on this 11% reduction. Consider a 65-year-old patient with a retinal detachment. In an independent practice, they’d get emergency surgery within 24 hours. In a PE-owned practice, they might get a referral to a different facility, a “let’s monitor it” approach, or a delayed surgery. That 24-hour window is critical. After that, the chance of permanent vision loss increases by up to 50%.
The study didn’t track individual patient outcomes. But the implication is clear: some people are losing their sight because a private equity firm needed to hit its margin targets.
What This Means for the B2B Ecosystem
Private equity’s impact on healthcare is a canary in the coal mine for every B2B tech company. The same dynamics—profit maximization, consolidation, and incentive misalignment—are playing out in dental, dermatology, and veterinary practices. If you’re selling into any of these verticals, the same playbook applies.
You Can Be the Solution
The best B2B tech companies don’t just optimize for efficiency. They optimize for outcomes. In healthcare, that means helping providers deliver the right care at the right time, even when it’s not the most profitable decision. If your product enables that, you’re not just selling software—you’re helping save sight.
The Data-Driven Ethical Advantage
Use the Harvard study as a case study. When you demo your product, show prospects how data transparency can prevent the kind of “silent rationing” that PE firms encourage. “Our dashboard flags when emergency cases are being deprioritized. It helps your physicians practice medicine, not meet EBITDA targets.”
Final Takeaway
The 11% reduction in emergency surgeries is a wake-up call. It proves that in the wrong hands, even the most noble professions can be twisted by profit motives. For B2B tech leaders, this is both a warning and an opportunity.
The warning: don’t blindly sell into a system that’s rigged against patient welfare. The opportunity: build tools that help providers resist that rigging.
Revenue teams at SaaS and tech companies serving healthcare have a choice. You can optimize for the quarterly report—or you can optimize for the patient who sees the light of day tomorrow because you prioritized emergency readiness over elective volume.
Choose wisely. The stakes are higher than your next renewal rate.
Are you selling into the healthcare provider market? Reach out to share your experience navigating PE-owned accounts. We’re building a community of revenue leaders who care about ethical growth.